ARQT News and Press, Arcutis Biotherapeutics Inc. From 05/05/22

Increasing commercial preparations in advance of our Prescription Drug User Fee Act (PDUFA) action date of July 29, 2022 for roflumilast cream for the treatment of plaque psoriasis in adults and adolescents Completed enrollment of the sole pivotal Phase 3 trials of roflumilast foa...

Topline data anticipated in late Q3/early Q4 A total of 432 subjects are enrolled in the ARRECTOR study Arcutis progressing topical roflumilast in four dermatological indications Over 3 million patients in the U.S. have plaque psoriasis in the scalp WESTLAKE VILLAGE, C...

Phase 3 data from the DERMIS Phase 3 trials demonstrated an excellent efficacy profile for roflumilast in psoriasis. The side effect profile was also excellent. Roflumilast has a PDUFA date in July and it is likely to be approved. Peak sales may reach $1B in psoriasis. Rof...

Differentiated profile of topical roflumilast aligned with unmet needs in multiple inflammatory dermatoses Well-prepared for the Company’s potential first launch ahead of PDUFA target action date of July 29 Clinical program for topical roflumilast continues to advance w...

Previously reported data demonstrated that roflumilast foam provided statistically significant improvement in disease severity and a favorable safety and tolerability profile Improvement on Investigator Global Assessment (IGA) Success and itch as early as week 2, the first timepoint m...

Pooled analysis of DERMIS-1 and DERMIS-2 demonstrated significantly more roflumilast-treated patients achieved Investigator Global Assessment (IGA) success (40%) at week 8 compared to vehicle (7%), consistent with results from the individual studies New post hoc analyses showed cons...

64% of adults with plaque psoriasis who are on topical treatments reported ever having psoriasis in intertriginous areas, higher than previous epidemiological studies suggest Around three in four people with symptoms in intertriginous areas reported a negative impact on their emotiona...

WESTLAKE VILLAGE, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, will host an Investor Day in Boston, MA on Monday, March 28, 2022 at ...

Goldman Sachs has initiated Arcutis Biotherapeutics (ARQT -2.5%) with a buy rating ahead of the potential approval of its first commercial product. The firm has a $45 price target (~163% upside based on Thursday's close). Analyst Chris Shibutani said that the stock price is "compelling at cur...

WESTLAKE VILLAGE, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 18,900 restricted stock u...